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1. ABSTRACT (175 words) 
 
The regulatory mechanisms involved in tendon homeostasis and repair are not fully understood. 
Accumulating data, however, demonstrate that the nervous system, in addition to afferent (sensory) functions, through 
efferent neuronal pathways plays an active role in regulating pain, inflammation, and tissue repair processes. 
Thus, in normal-, healing- and tendinopathic tendons three major neuronal signalling pathways consisting of 
autonomic, sensory and glutamatergic neuromediators have been established. In healthy tendons, these neural elements 
are found in the paratenon, whereas the proper tendon is practically devoid of nerves, reflecting that normal tendon 
homeostasis is regulated by pro- and anti-inflammatory mediators from the tendon surroundings. During tendon repair, 
however, there is extensive nerve ingrowth into the tendon proper and subsequent time-dependent appearance of 
sensory, autonomic and glutamatergic mediators, which amplify and fine-tune inflammation and tendon regeneration. 
In tendinopathy, excessive and protracted sensory and glutamatergic signalling may be involved in inflammatory, 
painful and hypertrophic tissue reactions.  
As our understanding of these processes improves, neuronal mediators may prove to be useful in the development of 
targeted pharmacotherapy and tissue engineering approaches to painful, degenerative and traumatic tendon disorders.  
 
2. INTRODUCTION  
 
Tissue repair after injury is a complex process, and usually depicted as a series of three to four overlapping 
sequences of molecular and cellular events (1, 2). These events are influenced by the site of the injury, age, sex, 
genetics, nutrition, co-morbidities, and a variety of other factors (1-4). The outcome of this coordinated series of events 
we label wound healing is usually tissue repair, not tissue regeneration, a limitation which can compromise the 
functional outcome of the healing process depending on the site of the injury. For instance, insults to internal organs 
such as the heart, lungs, liver, and kidneys can lead to wound healing-like fibrotic processes that can lead to deposition 
of scar-like material with little functional capability (5). While most soft tissues (e.g. skin, ligaments, tendons) heal via 
a repair process, some tissues (such as bone) can regenerate after a fracture, in part due to the nature of the bone 
remodeling process (3, 4). 
 
The goal of most tissue repair in post-natal life is the restoration of the integrity of the tissue even if it is compromised. 
Thus, injury to the skin leads to development of granulation tissue which remodels over time, but in the meantime the 
scar tissue prevents loss of nutrients from the organism, and limits the potential for infection.  Interestingly, tissue 
repair following certain types of injury to specific tissues in utero can lead to outcomes more resembling regeneration 
than the fibrotic repair discussed above. The molecular and cellular basis for these differences between post-natal 
healing and early in utero healing has been the subject of intense investigation (6, 7), and it would appear that at least 
some of the distinction is at the level of differences in the inflammatory response of the organism in the two 
environments (6, 8), with the inflammatory response in utero being somewhat muted and the involvement of specific 
cytokines/growth factors altered compared to the post-natal situation (9, 10). Whether this early in utero response is 
overt or is a consequence of the altered immune status induced by the mammalian fetal-maternal relationship during 
pregnancy is not yet clear. It is clear that later in gestation (e.g. equivalent to the third trimester of a human pregnancy), 
tissue repair following injury becomes more and more similar to post-natal responses (11).  
 
Thus, a muted inflammatory response appears to work in favour of better healing in some circumstances. However, a 
compromised inflammatory response associated with diseases such as diabetes (a prevalent co-morbidity particularly in 
the older population with type 2 diabetes; discussed in Purkayastha and Cai, 2013 (12); Hellman et al., 2012 (13); 
Mirza et al., 2013 (14)), can exert a negative effect on healing, leading to chronic wounds and life-threatening 
complications (15). Oppositely, excessive or unregulated inflammation may result in abnormal healing, with fibrosis or 
disruption of the integrity of the tissue function (16). Thus, in a subset of elbow injuries involving the joint capsule (for 
reasons currently unknown), an abnormal, and apparently exuberant inflammation results in compromised function and 
joint contractures (17). Finally, “inflammation” can be induced via endogenous or exogenous mechanisms, and 
sometimes can be confused with tissue catabolism since some of the same mediators may be involved (18). Therefore, 
the key elements relate to regulation and the “Yin and Yang” of balanced responses to yield effective outcomes without 
loss of tissue integrity after an injurious insult (19). 
 
As indicated in the above discussion, inflammation plays an important role in initiating and regulating tissue repair 
following an injury. With the exogenous inflammatory response into an injury site is an influx of circulation-based 
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inflammatory cells (polymorphonuclear cells, monocytes/macrophages, mast cells) with concomitant expression of a 
cascade of soluble inflammatory mediators, cytokines and growth factors (20). In response to this environment, the 
local fibroblasts and other cells in the site together with recruited exogenous mesenchymal stem cells or progenitor 
cells start to proliferate, migrate and differentiate to synthesize a provisional matrix. This is accompanied by 
neovascularization to provide blood vessels to support the metabolic activity. Subsequently, over time the matrix 
remodels, many of the cells in the wound site disappear or undergo apoptosis, and the neovasculature regresses. 
Ultimately this leaves a somewhat modified matrix compared to the original, and cells populating the matrix that are 
different from those in the site originally. In tissues highly adapted to perform specific mechanical functions, such as a 
ligament or tendon, this modified matrix (or scar) rarely functions as well as the original tissue, a situation that could 
lead to impaired motor performance, or joint dysfunction, including osteoarthritis and/or decreased survival in an 
animal in the wild. 
 
Much of what we know about normal tissue repair/wound healing has come from studies that have focused on skin 
wound healing (1, 2, 21, 22), as well as the healing of other soft tissues such as tendons and ligaments. The emphasis 
has been on what many investigators believe to be the major contributors to outcomes, namely the most prominent cell 
types involved in the inflammatory responses, the quantity and quality of the matrix formed, and the regulation of the 
neovascularization events. Conversely, how these components are altered in compromised healing/repair due to co-
morbidities such as diabetes, associated with chronic wounds in patients who are either aged and/or have compromised 
cardiovascular systems, or in patients taking certain drugs for other conditions, has also been the subject of intense 
investigation due to the impact of loss of tissue repair capabilities on survival, quality of life, and cost to the health care 
system. 
 
Recently, more attention has focused on a system that has not normally been the topic of much research attention as it 
is not prominent in many of these tissues (e.g. skin, ligaments and tendons), and therefore the contribution of neural 
elements to normal tissue function, the response to injury in a variety of circumstances, and compromised tissue repair 
is only now starting to become the subject of more investigation.  The view of the peripheral nervous system as a 
passive “messenger”, conveying information about tissue injury to higher centres, has been superseded by the view that 
neural regulation is actively involved in repair processes, even if the relative contribution based on “cell” number in 
these tissues is small, since a regulatory system by its nature should likely be in such a situation so as not to interfere 
with function. Normally, connective tissues such as ligaments, tendons, menisci, and intervertebral discs are considered 
hyponeural, and tissues such as articular cartilage are aneural, and do not heal or repair well. However, while present at 
low density, neural elements can contribute to tissue regulation and response to injuries (both subclinical and overt) via 
release of potent neuropeptides that can modify the activity of normal fibroblast-like cells in such connective tissues 
(23, 24), and interact with endogenous inflammatory cells such as resident mast cells and macrophages to amplify their 
influence (25-27) and regulate the functioning of the microvasculature present in these tissues or occurring in response 
to  neovascularization stimuli. 
 
An example of such “amplification” of neural impact on normal tissue homeostasis, as well as during normal and 
abnormal healing is what has been termed the “Neural-Mast Cell-Myofibroblast/Fibroblast Axis” (17, 26). This 
postulated axis of influence has been partially characterized during skin wound healing in domestic pigs (28), flexor 
tendon healing in a rabbit model (29), in a rabbit model of joint injury with joint contracture formation (17) (30), and 
possibly in human tendinosis tissue (31). Recent in vivo (32) and in vitro studies have supported the concept using 
tendon cells  or cells from human joint contractures (Hildebrand et al., submitted) in fibroblast-mast cell-neuropeptide 
collagen gel contraction studies. Thus, the neural influence could be amplified via such mechanisms and impact both 
normal and abnormal healing if injured tendons and other connective tissues.   
 
While the neural elements in normal and repairing connective tissues are not present at high density, due to the 
complexity of different types of neural elements and their associated neuropeptides and functions, it is not yet clear 
how the specific contributions of unique components of the neural system are themselves regulated, and how the 
integrity of these components regulate outcomes of the repair process. Therefore, we present the current state-of-the-art 
with regard to neural influences on connective tissue healing, with a focus on tendons. Obviously, there may be site- or 
tissue-specific involvement of the neural system in maintenance and repair of tendons, but there may also be some 




One key point that should be emphasized is that neural influences are dynamic across the lifespan. It is known that 
innervation of some tissues declines with age (and may be influenced by genetics) (33, 34). It is also known that 
sex/gender can influence inflammatory pathways and neural impact (35). Thus, this dynamic nature may complicate 
interpretation of findings, but it also offers insights into regulatory points that may lead to new approaches to overcome 
deficits or excessive involvement in healing processes. 
 
3. CENTRAL NEURONAL PATHWAYS  
 
 There are three major neuronal pathways by which the central nervous system regulates the 
inflammatory healing reflex that may be the most critical step in the repair process. The autonomic and sensory 
neuronal regulatory systems in combination with the glutamatergic excitatory system modulate inflammatory and 
trophic cellular response mechanisms through a combined release of classic nerve transmitters and so called 
neuropeptides (Table 1). The presence of contralateral changes in animal models of tendinopathy is highly suggestive 
of a key role of the central nervous system in this process (36, 37). Furthermore, recent studies have also indicated a 
contralateral effect during calcium deposition following injury in a murine Achilles tendon injury model (5). A mis-
tuned inflammatory healing reflex by, for example, inadequate or excessive neuronal signalling can lead to deficient 
repair or even chronic tendon disorders (38, 39). Evidence of central pain sensitization exists in clinical studies of 
patients undergoing shoulder acromioplasty surgery for tendinopathy of the rotator cuff (40).  
 
3.1. Autonomic regulation 
3.1.1. Sympathetic innervation  
The sympathetic nervous system regulates inflammation at local and systemic levels through the release of 
norepinephrine (noradrenaline) together with neuropeptide Y (NPY). Activation of the sympathetic outflow by flight-
or-fight responses or pain can increase local concentrations of adrenaline and noradrenaline, capable of suppressing 
inflammation (38). Adrenergic and Y (NPY) receptors on immune cells allow the immune system to respond to 
neuromediators released from sympathetic nerves and thereby establish a neuro-immune coupling.  
 
3.1.2. Parasympathetic innervation 
The parasympathetic nervous system likewise regulates the inflammatory reflex at local and systemic levels through 
the combined release of acetylcholine (Ach) and the neuropeptide vasoactive intestinal polypeptide (VIP). 
Parasympathetic activation of the vagus nerve is called the ‘cholinergic anti-inflammatory pathway’ because it leads to 
mediator release in multiple organs of the body (38). Ach and VIP then interact respectively with nicotinic (ACh 
receptor) and VIP-receptors on tissue macrophages, which inhibit the release of pro-inflammatory cytokines (eg. TNF, 
IL-1, HMGB1).  
 
3.2. Sensory regulation 
Interestingly the sensory nervous system seems to act principally through release of slowly acting mediators, i.e. 
neuropeptides. Recent research has additionally disclosed the classical transmitter glutamate in sensory nerve fibers 
demonstrating an interaction between neuropeptides and classical transmitters in sensory fibers as well.   
 
3.2.1. Sensory innervation  
The paradoxical “efferent” role of afferent sensory fibers is now widely recognized (41). Sensitization of the primary 
afferent nociceptive nerves gives rise to altered stimulus–response coupling, leading to release of sensory 
neuropeptides eliciting the so-called neurogenic inflammation. The sensory neuropeptides consist of five tachykinin 
peptides: substance P (SP), neurokinin A (NKA), neuropeptide K, neuropeptide-g, and neurokinin B and calcitonin 
gene-related peptide (CGRP), which coexists with and potentiates the effect of SP (42-44). Immune cells that appear 
during the different phases of healing express sensory neuropeptide receptors, allowing them to be regulated (45). SP 
and CGRP exert pro-inflammatory effects such as vasodilation and protein extravasation (46, 47). An interesting 
example of the “efferent” role of afferent sensory fiber stimulation is depicted in a unilateral overuse model for 
Achilles tendinopathy. An increase in SP also in the unexercised control legs of an animal model points towards the 
involvement of descending neuronal pathways in tendinopathy development (37).   
 
3.2.2. Opioid and opioid like signalling 
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The sensory nerve fibers also contain peptides with anti-inflammatory effects counteracting the effects of SP and 
CGRP. Thus, galanin (GAL), somatostatin (SOM) as well as opioid peptides (enkephalins, dynorphins, endomorphins), 
all of them occurring in primary afferents, inhibit inflammation and nociception (48-51). 
 
3.3. Glutamatergic regulation  
Accumulating data support the notion that modulation of glutamate receptors, ionotropic (NMDA, AMPA, Kainate) 
and metabotropic (mGlu), may have potential for targeted therapy in several persistent pain conditions, including 
neuropathic pain resulting from injury and/or disease of central or peripheral nerves and inflammatory or joint-related 
pain (e.g., rheumatoid arthritis, osteoarthritis, tendinopathy). Persistent pain is postulated to depend, at least in part, on 
long-term increases in synaptic efficacy of glutamatergic signalling in central nociceptive pathways, often called 
central sensitization (52). 
 
AMPA receptors are present in both myelinated and unmyelinated sensory nerves of rat (GLUA1) and human skin 
(GLUA2–3). Increased levels of glutamate and the AMPA receptor have been shown in experimental arthritis, suggesting 
that enhanced glutamate release acting on peripheral AMPA receptors may contribute to the initiation of nociceptive 
signalling. Activation of both peripheral and central NMDA receptors as well has been implicated in pain processing 
(53, 54). There also appears to be an interaction between neuropeptides and glutamate. Thus, SP has in the central 
nervous system been demonstrated to remove a magnesium ion from the NMDA receptor, which enables glutamate to 
bind, thereby initiating nociceptive transmission.  
 
Nociceptive afferents are mostly divided into two groups: peptidergic (SP-positive) and non-peptidergic, which 
typically express ATP-activated P2X3 receptors. Kainate receptors immunoreactive to GLUK5 mostly display P2X3- 
compared to SP-immunoreactivity, suggesting a greater role for the kainate receptor (GLUK5) in neuropathic than 
inflammatory pain conditions (52). 
 
Also, the metabotropic receptors (mGlu1 and mGlu5), which are known to potentiate the NMDA receptor excitation, 
are expressed in dorsal root ganglia cell bodies and peripheral terminal endings, suggesting that there are multiple loci 
for modulation of primary afferent sensory transmission. 
 
4. PERIPHERAL NEURONAL PATHWAYS  
 
The same pathways with nerve transmitters and neuropeptides occurring centrally are also found peripherally 
(Table 1). The presence of nerve fibers, including various neuromediators in tendon, has been demonstrated by 
combined quantitative and morphological assessments with an almost identical neuroanatomy of rat and human tendons 
(31, 55-57).  
 
4.1. Autonomic pathways 
4.1.1. Sympathetic innervation  
The occurrence of sympathetic mediators has been demonstrated in tendons of both animals and humans (58-61). 
Noradrenaline (NA) and neuropeptide Y (NPY) were mostly observed as networks around larger blood vessels located 
in the loose connective tissue around the main body of the tendon (Figure 1A-B). These observations would reflect that 
the sympathetic tendon vasoregulation predominantly occurs in the tendon envelope, i.e. the adjacent loose connective 
tissue. 
Adrenergic receptors have been identified on tendon cells, blood vessel walls and on nerve fibers (59, 60, 62). 
Moreover receptors for NPY, the Y1-receptor has been identified on tendon cells and blood vessel walls, whereas the 
Y2-receptor was not identified in the tendon biopsies (63). Adrenergic stimulation of tendons may be involved in cell 
proliferation of fibroblasts, tenocytes, endothelial cells and possibly nerve sprouting, which all are characteristics seen 
in tendinosis. 
 
Elevated sympathetic activity is also known to act in an anti-inflammatory fashion by inhibiting macrophage activation 
and suppressing synthesis of tumor necrosis factor (TNF) and other cytokines (38). Interestingly NPY has been 
demonstrated as a potent immune mediator with both pro-inflammatory and anti-inflammatory actions (64, 65).  
 
4.1.2. Parasympathetic innervation  
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The parasympathetic mediators acetylcholine and VIP were both identified in tendon (58, 66, 67). Nerve fibers 
displaying immunoreactivity to VIP have been observed as long thin varicose nerve terminals forming a “fence” in the 
paratenon (Figure 1C). The nerve fibers were evenly distributed between vascular structures and free nerve endings.  
 
As opposed to sympathetic (NA/NPY) nerve terminals occurring mostly in larger vessels, VIP has predominantly been 
found around smaller vessels (58, 61, 68). This observation may reflect that NA and NPY (vasoconstrictive) 
predominantly regulate the main blood flow to the tendon proper, whereas VIP (vasodilatory) is responsible for the 
fine-tuning of blood flow at a microlevel (58). 
The non-vascular distribution of VIP would seem to comply with an anti-inflammatory effect in the periphery (Figure 1C) 
(69-71). The strong anti-inflammatory role of VIP has been suggested to act through inhibition of T cell proliferation and 
migration (64, 71-73). 
 
Acetylcholine (Ach) receptors have been identified on tendon cells and blood vessels (66, 67), while VIP receptors 
(VPAC1, VPAC2 and PAC1) have yet to be explored in tendons. Ach receptors located on tissue macrophages may be 
involved in the so called cholinergic anti-inflammatory pathway, inhibiting the release of pro-inflammatory cytokines (38). 
 
Interestingly, the expression of the nicotinic receptor-alpha7, which is an essential regulator of inflammation by 
inhibiting tumor necrosis factor release from macrophages, has in tendon been found during early development and 
hence could be important during embryogenesis (74). Also, nicotinic receptors have been detected at the myotendinous 
junction and are suggested to promote repair by regulating cell fusion (75). The occurrence of nicotinic receptors in 
tendons and their function, however, need further exploration.  
 
Overall, mapping of para-/sympathetic mediators in tendon has opened a link to increased understanding of autonomic 
neuro-immune modulation in tendon homeostasis.  
 
4.2. Sensory pathways   
4.2.1. Sensory innervation  
The occurrence of sensory neuropeptides SP, CGRP and NKA in tendons of both animals and humans has been 
disclosed (Figure 2A)  (Table 1) (61, 76-79). Sensory nerve fibers have been found in the tendon envelope, i.e. the 
paratenon, endotenon and surrounding loose connective tissue, whereas the tendon proper, notably, during normal 
condition is devoid of nerve fibers (Figure 3) (80). This would reflect that the neuronal regulation of tendons highly 
depends on the innervation of the tendon envelope. 
 
Thus, the abundance of vascular sensory nerve fibers detected in the surrounding loose connective tissues may reflect 
an important role in the regulation of blood flow to the tendon structures. Both SP and CGRP, in particular the latter, 
have been reported to be potent vasodilators (81). In addition, they have also been demonstrated to exert pro-
inflammatory effects, for example by enhancing protein extravasation, leukocyte chemotaxis and cytokine production 
(46, 47). The occurrence of sensory free nerve endings unrelated to vessels predominantly seen in the paratenon (Figure 
2A) suggests nociceptive, trophic and immune regulatory roles.  
 
4.2.2. Opioid and opioid like signalling 
The peripheral sensory nervous system exhibits an opioid and opioid-like source of anti-inflammatory and anti-
nociceptive neuropeptides to modulate the sensory system (82-85). However, data on opioids in the peripheral nervous 
system and specifically tendons are quite scarce (Table 1). Notably, the existence of an opioid system in tendons has 
been established in the rat (86). The results clearly demonstrated the occurrence of opioid peptides (enkephalins and 
nociceptin) and opioid-like peptides (GAL, SOM) in the tendon (Figure 2B-C).  
 
Thus, all four enkephalins detected (LE, ME, MEAP, MEAGL), as well as GAL and SOM, predominantly occurred in 
sensory C-fibers localized in the tendon envelope, i.e. the paratenon, loose connective tissue, and musculo-tendinous 
junction, whereas no opioids were found in the proper tendon tissue (Figure 2C). This difference in anatomical 
distribution might suggest that regulation of painful disorders of the tendon mainly occurs in the surrounding tissues, 
which, during normal conditions, also harbour the sensory and autonomic neuropeptides. 
In the loose connective tissue surrounding the tendon, the opioid and opioid-like neuropeptides appear as free nerve 
endings around the walls of both large and small blood vessels, which may reflect involvement in both vasodilatory actions 
(87) and anti-inflammatory responses (Figure 2D) (88, 89). In the paratenon and the musculo-tendinous junction, the 
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opioid and opioid-like peptides mostly occurred in free nerve terminals without any relationship to blood vessels 
suggesting a paracrine or an autocrine function in the regulation of nociception (Figure 2C) (48, 90, 91). Such a regulation 
is probably executed in close interaction with the sensory nervous system. Thus, the release of the sensory neuropeptide SP 
from afferents in the cat knee joint is inhibited by intra-articular enkephalin-analogue injections (92). Whether there is an 
inherent balance between opioid and sensory neuropeptides under normal conditions is unknown. 
 
The existence of an opioid system in tendons consisting of neuronal enkephalins was supported by the identification of 
opioid receptor analyses based on binding assays and immunohistochemistry (56). Of the three opioid receptors (DOR, 
KOR, MOR) studied, however, only DOR could be detected by immunohistochemistry (Figure 2C). Double staining 
disclosed co-existence of each of the enkephalins with DOR in the nerve fibers, in accordance with other studies 
suggesting that enkephalins are the main ligands for DOR (93). 
 
The presence of peripheral opioid receptors was corroborated by receptor binding analysis, showing that tendon tissue 
could bind the competitive opioid receptor agonist, naloxone, in a specific and saturable way. DOR activity has been 
demonstrated to exert a potent inhibitory effect on SP-release (92, 94). Treatment with delta opioid agonists in the 
periphery elicits both anti-inflammatory and anti-nociceptive effects in models of inflammation (95). Thus, peripheral 
acting opioid agonists may prove effective in preventing the symtoms associated with tendinopathy  (96). 
 
Depiction of sensory and opioid pathways in the tendon envelope suggests an intricate homeostatic balance in 
nociception, trophic actions and immune regulation occurring in the tendon surrounding structures. 
 
4.3. Glutamatergic regulation 
Glutamate transmission, which occurs in the central nervous system, has recently also been shown to take place in the 
peripheral nervous system through interaction with its ionotropic (AMPA, NMDA, kainate) and metabotropic receptors 
(mGlu) (97).  
In tendon, both the ligand glutamate and the NMDA- as well as several mGlu receptors have been identified (Table 1). 
Both glutamate and its receptors have been identified in nerve fibers, blood vessels and tendon cells. Likely sources of 
glutamate production may be nerve fibers and, in tendinopathy, the tenocytes themselves (98-100). More information is 
available in the section on neuronal responses to tendinopathy. Peripheral glutamatergic regulation may be involved in 
the maintenance of tendon strength, cell proliferation, differention and in pathological cell transformation (97, 99). 
Moreover, the peripheral glutamate signalling has been implicated in tendon tissue repair (101, 102). 
 
Overall, in tendons there seems to exist similar neuronal pathways consisting of different autonomic, sensory, opioid 
and glutamate neuromediators as observed in other organs of the body. One important conclusion on tendon 
neuroanatomy is that the tendon proper during normal conditions is devoid of nerve fibers, while innervation is found 
in the tendon envelope, i.e. the paratenon, endotenon and surrounding loose connective tissue (Figure 3A-C).  
Another vital feature of the neuronal pathways which appears is the balance between different mediators, i.e. pro- and 
anti-inflammatory peptides. These observations would suggest that homeostatic regulation of healthy tendon tissue is 
highly dependent on balanced neuro-immune-mediator modulation occurring in the tendon envelope. 
 
5. NEURONAL RESPONSE TO TENDON INJURY  
 
There is anatomic evidence of dynamic peripheral neuronal responses to tendon injury in a rat model of 
Achilles tendon rupture. Axonal sprouting and growth and a time dependent expression of neuropeptides have been 
found to occur during healing of Achilles tendon rupture in the rat (Figure 4-6) (80, 103). Similar reactions can be 
observed in other tendons and in human tendon repair as well (29, 102, 104). The study presented was conducted using 
immunohistochemistry including a semi-quantitative assessment focusing on the rupture site of the proper tendinous 
tissue. Neuronal markers for regenerating and mature fibers, ie. growth associated protein 43 (GAP) and protein gene 
product 9.5 (PGP), respectively, were analyzed at different time points (1 to 16 weeks) post-rupture. The temporal 
expressions of sensory and autonomic neuromediators were assessed at the same time points.  
 
5.1. Inflammatory phase 
In the first week post rupture, the increased occurrence of neuronal markers indicates nerve regeneration both in original 
nerve fibers of the tendon envelope, i.e. paratenon and surrounding loose connective tissue, and, notably, in new nerve 
fibers in the proper tendon tissue of the rupture site (Figure 4).  
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In the proper tendinous tissue, normally devoid of nerves, there was a clear GAP-immunoreactivity suggesting new nerve 
fiber ingrowth, which is consistent with reports on GAP levels in dorsal root ganglia after peripheral nerve injury (Figure 
5) (105, 106). GAP may be involved in nerve regeneration by regulating growth cone motility and axon guidance signals 
(107). These observations of early nerve regeneration are in line with observations on bone, ligament and skin healing 
indicating that nerve ingrowth is a fundamental aspect of tissue healing  (22, 108-111).  
 
5.1.1. Autonomic regulation 
At 1 week post injury, there was only weak scanty expression of sympathetic (NPY) and parasympathetic (VIP) mediators. 
These findings suggest suppressed anti-inflammatory effects of the autonomic nervous system during the inflammatory 
phase. 
 
5.1.2. Sensory regulation 
At 1 week, SP and CGRP nerve fibers were predominantly located in blood vessel walls surrounded by inflammatory cells 
in the loose connective tissue (Figure 8A). The findings comply with the nociceptive role of sensory neuropeptides, but 
also with a pro-inflammatory role. Thus, SP release enhances vasopermeability, probably to stimulate recruitment of 
leukocytes and cytokine production (112-115). The opioid like mediator GAL only showed weak expression, reflecting 
low anti-inflammatory actions (Figure 6).  
 
5.1.3. Glutamatergic regulation 
During the first week post tendon injury, microarray- followed by real-time PCR analyses demonstrated an up-
regulation of glutamatergic signalling molecules involved in activation of the metabotropic glutamate receptor type 1 
and the NMDA receptor (116). The localisation of the NMDA receptor on tendon cells was further evidenced by 
immunohistochemical staining.  
It is plausible that the glutamatergic system is used to coordinate some aspects of tendon healing as has been shown in 
development and maintenance of bone tissue (97). An interesting observation was the fact that the expression of 
glutamatergic signalling molecules during tendon repair demonstrated a temporal relationship to genes involved in 
embryonic development (116). 
 
5.2. Proliferative phase 
From 1 to 6 weeks post rupture, there was a striking shift in neuronal occurrence from the surrounding loose connective 
tissue into the proper tendinous tissue. This would seem to reflect the transition of a predominantly inflammatory into a 
proliferative phase. The peak expression of GAP-immunoreactivity at the rupture site occurred between week 2 and 6, 
while that of PGP occurred somewhat later, i.e. between weeks 4 and 6 (Figure 5). The extensive ingrowth of new nerve 
fibers into the rupture site probably represents a neuronal involvement in tendon repair. The observed free nerve endings 
among fibroblasts in the tendinous tissue may reflect a stimulatory role in cell proliferation (Figure 4B) (117). The 
occurrence of free nerve endings around newly formed blood vessels at the rupture site suggests a role in vasoregulation, 
and possibly in angiogenesis (Figure 7) (118). 
 
5.2.1. Autonomic regulation  
During the proliferative phase, the occurrence of the autonomic mediators NPY and VIP was sparse until week 4. 
Subsequently, the expression increased to reach a peak at the end of the regenerative phase, ie. at about week 6, followed 
by a successive decrease.  
The observations of low sympathetic (NPY) innervation would reflect that vasoconstriction is downregulated during tissue 
repair. The balance between the vasoconstrictive actions of NPY and the vasodilatory actions of CGRP is of decisive 
importance for the supply of oxygen and nutrients to the healing area. The high ratio of CGRP to NPY in the proliferative 
phase of healing probably represents highly perfused vessels, a necessity for tissue repair. Similar observations on the ratio 
CGRP to NPY have been made in studies on reinnervation of skin flaps, where CGRP immunoreactivity emerged at 2 
weeks postoperatively and that of NPY 2 weeks later (119, 120). The low levels of NPY observed may also promote 
angiogenesis (121). 
 
The reduced expression of parasympathetic VIP appears surprising considering the need of vasodilation during tissue 
repair. However, the low occurrence of VIP possibly pertains to its inhibitory action on the pro-inflammatory effects of SP 
and CGRP (69). Thus, the observation suggests less inhibition of SP and CGRP, which are presumed to be important 
regulators of early tissue repair.  
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5.2.2. Sensory regulation 
During weeks 1 to 6, the expression of SP and CGRP peaked (Figure 6). Notably, this peak occurred at the rupture site of 
the proper tendon, while the sensory neuropeptide expression in the surrounding loose connective tissue declined. The 
latter would seem to comply with decreased pain 3-4 weeks after injury, which is substantiated by a recent microdialysis 
study demonstrating resolving inflammation after two weeks post tendon rupture (122). The most conspicuous finding, 
however, was the occurrence of SP and CGRP in free sprouting nerve endings among fibroblasts in the healing tendinous 
tissue (Figure 8B). The observation might reflect a stimulatory role of sensory neuropeptides on cell proliferation, as 
demonstrated in cultured fibroblasts (117, 123).  SP and CGRP are also known to stimulate proliferation of endothelial 
cells (124-126). The observation of free sprouting SP- and CGRP fibers around newly formed blood vessels in the rupture 
site would comply with a role in angiogenesis (Figure 7). Recently, SP has also been demonstrated to exert an important 
role in stem cell mobilization during tissue repair (127).   
 
The reduced occurrence of the opioid-like GAL presumably pertains to its inhibitory action on the pro-inflammatory 
effects of SP and CGRP (128-130). 
 
5.2.3. Glutamatergic regulation 
At two weeks post tendon injury, microdialysis followed by quantification demonstrated a 3-times  up-regulation of 
glutamate levels in the paratenon of the healing tendon (102). Of all metabolites assessed during healing glutamate 
exhibited the highest elevation (102). This observation further strengthens the conception that the glutamatergic system is 
involved in regulating some aspects of proliferative tendon healing. Hypothetically, glutamate signalling molecules may be 
involved in regulating cell proliferation and differentiation as has been shown in other tissues (97).   
 
 
5.3. Remodelling phase 
During weeks 6 to 16 post-rupture the nerve fibers appeared to regress from the proper tendon tissue (Figure 5). While 
GAP-immunoreactivity almost completely disappeared during this phase, that of PGP successively returned to normal in 
the paratenon and surrounding loose connective tissue. The process appeared to end simultaneously with the completion of 
paratenon repair.  
 
5.3.1. Autonomic regulation 
Between week 4 and 6, corresponding to the transition of the proliferative into the remodeling phase, there was a dramatic 
increase in the expression of the autonomic neuropeptides VIP and NPY. The increase in the immunoreactivity for VIP 
and NPY was observed both around vessels and in free nerve endings in a “border zone” enveloping the healing tendon.  
 
The upregulation of parasympathetic VIP may be explained by its inhibitory effect on immune cells expressing pro-
inflammatoy cytokines (131). The increased occurrence of sympathetic NPY during this phase, mostly seen around 
vessels, should probably be attributed to its vasoconstrictive actions. Notably, increased vasoconstriction leads to a relative 
hypoxia, which enhances the tensile strength of the tendon by switching production of collagen from type III to type I 
(132). 
 
5.3.2. Sensory regulation 
Between week 4 and 6, matching the upregulation of autonomic neuropeptides, an increased occurrence of the opiod like 
GAL was observed both around vessels and in free nerve endings enveloping the healing tendon (Figure 6). The 
emergence of GAL, known to modulate the effect of sensory neuropeptides, would seem to comply with inhibition of the 
early inflammatory and nociceptive response to injury. Thus, GAL has been demonstrated to mitigate the proinflammatory 
and nociceptive effects of SP (49-51, 128). 
 
Subsequent to the elevated expression of GAL and the autonomic neuropeptides, a significantly decreased expression of 
SP and CGRP followed (Figure 6). Thus, the early remodelling phase after tendon injury seems to be characterized by an 
increased expression of GAL, VIP and NPY, all of which are known to modulate the effects of SP and CGRP. It may well 
be that this modulation is required to end the nociceptive, inflammatory and reparative processes, thereby permitting entry 
to and maintenance of the remodelling phase.  
 
5.3.3. Glutamatergic regulation 
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At six weeks post tendon injury, microdialysis followed by quantification demonstrated resolving glutamate levels as 
compared to the proliferative phase in the paratenon of the healing tendon (Ackermann et al. - unpublished data). The 
temporal expression of glutamate signalling during tendon healing seems to correspond to that of the sensory mediators. 
This observation may suggest that the glutamatergic system could interact with sensory mediators in regulating cell 
proliferation and differentiation during proliferative tendon healing.   
 
 
On the whole, the observations during tendon healing clearly demonstrate the capability of the peripheral nervous system 
to adapt and respond to an injury. This plasticity is characterized by nerve fiber ingrowth into the rupture site, and a peak 
nerve fiber expression during the proliferative phase followed by nerve fiber withdrawal. Interestingly, new nerve 
ingrowth provides a delivery route for neuronal mediators that are required for tissue repair. Subsequently, the temporal 
expression of the different neuropeptides studied implies specific actions to regulate the inflammatory, proliferative and 
remodelling healing phases. Thus, the end effect on tissue healing will depend on the nerve fiber localization, temporal 
neuropeptide expression and cellular receptor expression. 
 
6. NEURONAL CONTRIBUTIONS TO TENDINOPATHY 
 
Interestingly, in tendinopathies with chronic pain and a failed healing response, altered neural elements have 
been noted in a variety of tendons from various locations (Table 2). However, the cause-and-effect relationship is 
currently an area under investigation in most instances for the nerve endings and neuropeptides in the pathology.  
 
With that limitation, immunohistochemistry analysis of tissue samples does demonstrate similar patterns of innervation 
in tendinopathy tissue as is seen during the proliferative phase of healing after tendon injury. Thus, chronic painful 
tendons exhibit new ingrowth of sensory nerve fibers (Figure 9) (78, 79, 133), which is also observed during tissue 
proliferation in healing tendons (80). In normal tendon repair, sensory nerve ingrowth is correlated with increased 
nociception (103). This inflammatory phase is followed by peripherally acting autonomic and opioid-like signalling, 
coinciding with decreased nociception (103). Hence, the neuronal dysregulation in tendinopathy, characterized by 
aberrant increase of sensory nerve sprouting and a deficient autonomic and opioid-like modulation, presumably triggers 
pain signalling and possibly also the hyperproliferative/degenerative changes associated with tendinopathy (Figure 10). 
The ongoing morphologic alterations may reflect protracted or failed healing. An important point related to this concept 
is the role of nerves and neuropeptides during an initial response to an insult leading to the first symptoms of 
tendinopathy versus their role during the chronic phases of the condition, phases that can lead to overt degeneration, 
and, in some instances, rupture of the tendon. Some neuropeptides may serve different functions during these different 
“phases”, or different neuropeptides could be involved. It has been postulated that a nerve/neuropeptide-mast cell-
tenocyte axis may play a role in tendinopathies and over-use syndromes (25-27), and recently it has been confirmed 
that higher mast cell numbers are present in human patellar tendinopathy tissue samples of patients with disease of long 
standing as compared to samples from more recent onset (134), and there may be a destruction of a fine equilibrium 
with the alterations to the neural components. Thus, some aspects of tendinopathy may be independent of such an axis, 
while others may involve this axis to amplify the impact on the tendon tissue. 
 
6.1. Autonomic regulation 
6.1.1. Sympathetic innervation 
Chronic painful tendons exhibit a decreased occurrence of sympathetic nerve fibers, immunopositive to noradrenaline. 
Microscopic analysis demonstrated that sympathetic nerves related to blood vessels were distinctively decreased in 
patients with tendinopathy (Figure 11) (58). Computerized image analysis confirmed a 50% drop in vascular nerve 
fibers immunoreactive to noradrenaline in the painful tendons (58). The reduction in vasoregulatory noradrenalin 
suggests a reduced blood flow and a suppressed anti-nociceptive function. A recent study demonstrated that 
noradrenaline release leads to secretion of opioids from leukocytes (90). Similarly, patients with painful rheumatoid 
arthritis exhibit a decrease in vascular innervation expressing noradrenaline (135). To counteract the decreased 
sympathetic innervation, immune cells in the synovia from rheumatoid arthritis patients respond by upregulating 
noradrenaline. Likewise, in tendinopathy patients an upregulated noradrenaline production has been suggested in 
morphologically altered tenocytes (60, 136). 
 
Adrenoreceptors for noradrenaline have also been identified in tendinopathy. Immunoreaction for the alpha1-
adrenoreceptor has been detected in blood vessel walls, nerve fascicles and tenocytes (60, 136). Adrenegic activation of 
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alpha1/2-adrenoreceptors has been demonstrated to stimulate cell proliferation and differentiation (137, 138). Thus, 
upregulated noradrenaline in tendon cells may stimulate the alpha1/2-adrenoreceptors and contribute to tenocyte 
excessive cell proliferation and differentiation. In contrast, decreased vascular innervation expressing noradrenaline 
may be compensated by the observed increased alpha1-adrenoreceptor immunoreactions in blood vessel walls of 
tendinopathic patients (60, 136).  More recently, alpha1-adrenoreceptor expression in tendon cells has been found to be 
associated with NPY expression (139), concluding a strong role of the sympathetic nervous system in peripheral 
tissues. 
 
6.1.2. Parasympathetic innervation  
The cholinergic innervation in tendinopathy appears to be relatively scarce. Neuronal immunoreaction to choline 
acetyltransferase, vesicular acetylcholine transporter and acetylcholinesterase in tendons is reported to be limited 
compared to other tissues investigated. However, whether cholinergic innervation in tendinopathy is significantly lower 
than that of healthy tendons is still unclear (66, 67, 140). 
 
Immunohistochemical studies have identified activated markers of cellular acetylcholine production in human 
tendinopathy, most prominently seen in morphologically altered tenocytes (66, 67, 140).  Immunoreaction to choline 
acetyltransferase and vesicular acetylcholine transporter has recently been detected in normal Achilles tenocytes (141). 
This suggests that resident tenocytes have the capability to produce acetylcholine, which is increased during tendinosis. 
This process implies that acetylcholine either is involved in regulating the tenocyte transformation seen in tendinopathy 
(142), or that acetylcholine synthesis is initiated in tenocytes in response to development of tendinopathy. 
 
Parasympathetic muscarinic acetylcholine receptors (M2) have been identified in human tendinopathy. Thus, M2-
receptors have been identified in tendon cells, blood vessel walls and nerve fibers (66, 67). The difference between 
normal and tendinopathic tendons consisted in an intense M2-immunostaining in morphologically altered tenocytes, 
which was not seen in normal tenocytes. The observations demonstrate an endogenous autocrine and/or paracrine 
acetylcholine and M2-receptor signalling in transformed tenocytes. M2-receptors have also been found to contribute to 
an increase in cell proliferation and hypercellularity, through an autocrine loop, which is replicative of the early stages 
of tendon healing (141). 
 
6.2. Sensory regulation 
6.2.1. Sensory innervation  
Immunohistochemical and semi-quantitative assessments have clearly demonstrated that tendinopathic tendons exhibit 
an increased number of sensory SP-positive nerve fibers (Figure 9) (78, 79, 133). Closer analysis revealed that the 
nerve fibers occurred mainly as thin, varicose, sprouting nerve terminals within the tendon proper. The observation of 
increased ingrowth of sensory nerves into the painful tendon proper, seen as sprouting free nerve endings, possibly 
represents nociceptors responding to mechanical stimuli by initiating pain signalling.  
 
The increase of the sensory neuropeptide SP in tendinopathy may, in addition to its role in nociception, reflect pro-
inflammatory and trophic actions (143). Thus, SP has been found to participate in inflammatory actions such as 
vasodilation, plasma extravasation, and release of cytokines. SP has also been reported to stimulate proliferation of 
fibroblasts (143) and endothelial cells, as well as the production of transforming growth factor beta in fibroblasts. 
Hence, SP may well contribute to the morphologic changes observed in early tendinopathic patients, that is, tenocyte 
transformation, hypercellularity, and presumably neovascularization, in conjunction with mechanical loading (37, 144), 
and may therefore precede tendinosis.  
 
The implications of the above mentioned effects of SP are all plausible with respect to tendon pathology since its 
receptor, NK-1, has been detected in tenocytes, blood vessel walls and in nerve fibers in tendinopathy (145). SP has 
further been shown to directly stimulate nociceptor endings in an autocrine/ paracrine manner. Similar actions could 
presumably occur in tendinopathy since the NK-1 receptor is present. 
 
6.2.2. Opioid and opioid like signalling  
To date there are very few publications on opioid and opioid-like signalling in tendinopathy. In line with a depressed 
opioid and opioid-like signalling in tendinopathy, immunohistochemical analysis detected a low occurrence of galanin 
(unpublished data, Ackermann et al.). However, a recent publication detected increased cellular expression of 
cannabinoid receptors in tendinopathy (146). 
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6.3. Glutamate pathways  
Elevated interstitial levels of glutamate have also been found in tendinopathy by microdialysis (147). Furthermore, the 
specific localization for the increased glutamate levels has just recently been established in tendinopathic patients (100, 
148). Thus, up-regulated glutamate occurrence is observed in morphologically altered tenocytes, in the endothelial and 
adventitial layers of blood vessel walls and in nerve fibers. Injection of glutamate has also been shown to provoke and 
maintain local prolonged tendon pain (149), potentially through both the ionotropic and metabotropic receptors. 
 
One receptor for glutamate, NMDA receptor 1 (NMDAR1) has been identified in tendinopathy. Recently, both 
subjective and quantitative assessments demonstrated a 9-fold increased NMDAR1 occurrence in tendinopathic 
patients (98, 99). This finding was corroborated by a study on rat supraspinatus tendon overuse likewise demonstrating 
NMDAR1 upregulation (116). 
 
Maybe the most intriguing finding regarding glutamatergic signalling is the recent report demonstrating that elevated 
glutamate co-existed with its up-regulated receptor NMDAR1 in nerve fibers, morphologically altered tenocytes and blood 
vessels (98), which may reflect cell-hyperexcitation involved in cell proliferation/differentiation. However, none of the 
controls exhibited neuronal co-existence of glutamate and NMDAR1 in contrast to prominent neuronal occurrence in all 
the painful tendons, which strongly suggests a role in pain regulation (98). 
 
Overall, the neuronal mediator contributions to tendinopathy seem to involve an intricate regulation of cell 
proliferation/survival and differentiation. However, at present it is unclear to what extent this is regulated by a cellular 
origin of neuromediators versus a neuronal origin of neuromediators. Current and emerging data may prove that a balance 
in neuromediator levels is critical for tendon tissue integrity and that dysregulated neurosignalling contributes to the 
morphological features, i.e. cellproliferation and celltransformation, associated with tendinopathy. 
 
7. MOLECULAR RESPONSES TO NEUROPEPTIDES AND NEURONAL INFLUENCES 
 
Denervation impairs the healing of skin, bone, ligament and tendon in a variety of animal models (150-155).  
In the medial collateral ligament, a tissue with many structural and functional similarities to tendon, denervation 
significantly attenuates the response to injury. Scars from denervated ligaments exhibit lower blood flow, diminished 
angiogenesis and decreased mechanical strength when compared to their normally innervated counterparts (155). 
 
7.1. Denervation effects on gene expression in healing ligament in vivo 
In rabbits, denervation induced significant differences in the mRNA levels for many genes of interest in the injured MCL 
at two weeks post-injury (156). 
 
7.1.1. Denervation increases mRNA levels for collagen I and III and TGF- ß1 
In the denervated injury group, mRNA levels for the matrix components collagen I and III were both increased at two-
weeks post-injury, in comparison to the non-denervated animals (p≤0.01). Significant differences were not detected at any 
of the other time points assessed. 
 
Similarly, mRNA levels for the growth factor TGF-ß were increased at two-weeks post-injury, in comparison to non-
denervated (p≤0.01) (Figure 2). VEGF and NGF mRNA levels were not significantly altered at any time points post-injury 
(p>0.01). 
 
7.1.2. Denervation increases mRNA levels for angiogenesis-associated matrix metalloproteinases (MMP-3, MMP-13 
and uPA) 
By two weeks post-injury, the mRNA level for angiogenesis-associated collagenase MMP-13 was increased almost 3-fold 
in the denervated group, in comparison to the non-denervated group (p≤0.01), and was 20 times the level found in normal 
ligaments.  MMP-3 and uPA mRNA levels appeared increased in the denervated injured ligaments at 2 weeks, but these 
apparent differences between the experimental groups did not achieve statistical significance at any time point. 
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7.1.3. Denervation increases mRNA levels for MMP inhibitors (TIMP-1 and TIMP-3) and the angiogenesis 
inhibitor thrombospondin-1 (TSP-1) 
At two weeks post-injury, mRNA levels for the angiogenic inhibitors TIMP-3 and TSP-1 in the denervated injury group 
were significantly increased compared to those in the non-denervated injury group (p≤0.01). Notably, mRNA levels for 
TSP-1 were significantly elevated in the denervated injured group at sixteen weeks post-injury (p≤0.01). Levels of mRNA 
for TIMP-1 were not significantly different between innervated and denervated groups at any time points. 
 
The study demonstrated that, in a denervated MCL, mRNA levels for many angiogenic and repair-associated genes are 
increased during the early stages of healing.  The majority of the significant differences between denervated and 
innervated ligaments were detected at 2 weeks following injury, where levels of six of eleven genes tested were 
significantly altered. Two weeks post-injury corresponds to the proliferative stage of wound healing in this ligament 
injury model. Levels of mRNAs for repair-associated molecules are at their highest 2-3 weeks following injury in the 
rabbit MCL (157). 
 
The denervation-induced increases in mRNA levels for numerous matrix-molecule and angiogenesis-associated genes 
are difficult to reconcile with the previous work in the same model showing that denervated ligaments heal poorly. 
Based on the current findings, several possible explanations exist. Firstly, a loss of neuropeptide stimulation may 
substantially diminish cellular proliferation in the denervated scar, negating the effect of increased mRNA levels. 
Secondly, the increased levels of mRNA for TIMP-1 and TSP-1 in denervated injured ligament could have an 
inhibitory affect on cell function and more specifically, angiogenesis (158). Finally, the timing and regulation of 
expression of various interacting genes are likely very important in the production of an organized, mechanically 
adequate scar, and the data suggested that denervation disrupted the timing and regulation of mRNA changes for many 
molecules important in healing. 
 
7.2. Neuropeptide effects in tissue culture 
Because of the complexity of the wound healing environment, investigators have sought to gains insights from the 
observation of cells or tissue specimens in culture where variables inherent to the in vivo environment (blood flow, 
mechanical loading, etc.) are controlled or eliminated. Cellular responses in the form of mRNA or protein production 
can be assayed in the presence or absence of specific mediators.   
 
Neuropeptide effects on normal and injured ligament in culture 
Recently it was reported that tissue cultured specimens of injured ligament respond to the addition of specific 
neuropeptides to the culture medium (159).  In this study, mRNA levels for numerous healing-associated molecules 
were significantly altered by individual neuropeptides. 
 
7.2.1. Neuropeptides downregulate expression of some growth factors 
TGF-ß1 mRNA levels were significantly depressed in 2 week post-injury ligament specimens cultured with 10-7 M 
CGRP and 10-7 M NPY compared to untreated specimens. SP had no detectable effect on TGF-ß mRNA levels in 
injured ligament.  TGF-ß1 mRNA levels in normal uninjured ligament and in 3 days post-injury ligament explants were 
not significantly affected by any of the neuropeptides employed.  
 
The mRNA levels for bFGF were also responsive to neuropeptide exposure, with significant depression detected at 3 
days post-injury with NPY, and at 2 weeks post-injury with SP and CGRP. 
 
Similarly, the mRNA levels for VEGF were significantly depressed by CGRP and NPY only at two weeks post-injury.  
 
7.2.2. Neuropeptides increase expression of inflammatory mediators 
IL-1 mRNA levels were significantly increased by NPY and SP in the 2 week post-injury specimens.  Similarly, NPY 
increased the mRNA levels for both TNF-α and COX-2 in 2 week post-injury specimens. 
 
7.2.3. Neuropeptides decrease expression of matrix molecules 
Type I Collagen mRNA levels were significantly depressed by SP in normal ligament specimens, by CGRP at 3 days 
post-injury, and by CGRP and NPY at two weeks post-injury. 
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Type III Collagen mRNA levels were significantly depressed by all three neuropeptides in the 2 week post-injury 
specimens. 
 
Biglycan mRNA levels were significantly lowered by CGRP in both the 3 day and 2 week post-injury specimens, and 
by NPY in the 2 week post-injury specimens. Lumican mRNA levels were significantly lowered by NPY in uninjured 
specimens but were not affected by any neuropeptide in any of the injured specimens. 
 
Thus, SP and NPY can induce increased mRNA levels for inflammatory mediators in specimens of injured ligament 
placed in culture at 2 weeks after injury.  In contrast, all three neuropeptides tested induced significantly lower mRNA 
levels for several molecules associated with healing in MCL scar, including growth factors, matrix molecules, 
excluding lumican, and some angiogenesis-associated proteins. These data are consistent with the results of the 
denervation study, and support the idea that the effects of denervation are largely the result of the loss of neuropeptide 
stimulation.  However, the results of both studies seem at odds with the previous in vivo data, showing that denervation 
impaired ligament healing in the rabbit model (155). 
 
A number of possible explanations could account for this apparent paradox. The three neuropeptides tested promote 
increased blood flow and/or angiogenesis (160-164). As angiogenesis is widely accepted to be the key determinant of 
the outcome of wound healing, neuropeptide induced increases in blood flow and accelerated angiogenesis might be 
more important to the outcome of healing than the observed changes in mRNA levels for matrix molecules and growth 
factors (165-170).  
Neuropeptides are also known to increase cellular proliferation (118, 121, 171, 172).  Cells stimulated to proliferate 
would potentially downregulate or stop producing matrix molecules or growth factors until their proliferative phase 
was completed.  Increased cellularity would likely subsequently lead to the formation of a larger, stronger scar in vivo, 
and could account for the superior healing of innervated ligaments. 
 
Importantly, not all potentially important neuropeptides known to be present in articular tissues were tested. Vasoactive 
intestinal polypeptide (VIP), somatostatin (SOM) and met-enkephalin, all present in articular tissues (76, 86, 173, 174), 
are also likely important modulators of cellular metabolism in healing ligament.  Future studies should address the 
influence of these mediators on healing and scar cell behavior, as the neuropeptide milieu in the healing ligament is 
likely very complex.  Furthermore, most of the significant effects on mRNA levels were observed at two weeks post-
injury.  This corresponds to the late inflammatory and early proliferative phase of healing in the rabbit MCL. The way 
cells in the scar respond to neuropeptides appears to be time dependent, with different effects seen at different times 
after injury (175).  Thus, testing specimens retrieved at longer intervals after ligament injury, with a broader variety of 
mediators, might reveal additional differences in response to neuropeptide stimulation. 
 
Only one concentration (10-7 M) of each neuropeptide was tested.  Physiologic levels of neuropeptides in healing 
ligaments or tendons are unknown.  The effects of these agents may be dose-dependent and different effects might be 
seen at lower concentrations.  
 In vivo, neuropeptides are produced in a temporally and spatially regulated manner by nerve fibers in close proximity 
to existing or newly forming vessels (76, 176).  During development, angiogenesis can be highly regulated by neuronal 
factors (177). It is not known whether a similar relationship is found in healing ligament, tendon, or other wounds.  
However, a highly localized down-regulation of matrix production would facilitate angiogenesis, which depends on 
MMP-mediated matrix digestion to produce a channel for proliferating endothelial cells to migrate into. Since all the 
neuropeptides tested to date are associated with increased blood flow and angiogenesis, the results would indicate that 
blood vessels and endothelium are likely the primary targets of these neuropeptides in early ligament healing (161-164, 
170). 
 
7.3 Diversity of Fibroblast Phenotypes 
 
In recent years a number of investigations have revealed that fibroblast behavior and activity is strongly determined by 
genetic and developmental factors, which are retained to a considerable extent in the tissue culture environment.  For 
example, one early study showed that when grown in three dimensional collagen gels, fibroblasts derived from cornea, 
tendon and dermis oriented very differently after 7 days, with corneal fibroblasts orienting into orthogonal sheets, 
tendon fibroblasts forming parallel bundles, and dermal fibroblasts remaining randomly oriented (178). 
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Much of our information about fibroblast behavior in tissue culture, particularly in the context of wound healing, comes 
from studies of dermal fibroblasts. Even within dermis, fibroblasts in derive from different embryonic precursors. 
Evidence continues to accumulate that there is considerable phenotypic diversity between fibroblasts found in different 
locations within a given tissue or organ (179). Thus neuropeptide effects on fibroblast behavior likely are specific to the 
tissue of origin, and this mandates a cautious approach to the interpretation of results derived from tissue culture based 
experiments. 
 
8. HEALING RESPONSE TO ALTERED NEURONAL PATHWAYS 
 
8.1. Inadequate neuronal signalling 
Several investigations have indicated that denervation impairs the mechanical properties of both normal and 
injured ligament. A chemical sympathectomy with continuous systemic administration of guanethidine (40 mg/kg/day) 
leads to degradation of the mechanical properties of the intact medial collateral ligament (MCL) of the knee joint in rats 
after only ten days of treatment (180).  Ligaments from treated animals had a larger cross-sectional area, a higher wet 
weight, a decreased modulus of elasticity and a decreased stress at failure.  Some of these structural changes might be 
explained by the significantly increased mRNA levels for the matrix degrading enzymes MMP-13 and cathepsin K, and 
increased ligament blood flow induced by chemical sympathectomy.  
 
As noted in the previous section, femoral nerve transection impairs healing of the medial collateral ligament in rabbits 
(155).  In that study, blood flow, angiogenesis and mechanical strength of the ligament scar were all significantly 
decreased in denervated limbs compared to normally innervated limbs, 6 weeks after injury.  Similar results have since 
been reported in rats, where surgical sympathectomy or femoral nerve transection each reduced failure loads of healing 
MCLs by 50% compared to normally innervated healing MCLs, at 2 weeks after injury (181). 
 
One study assessed Achilles tendon healing after performing a specific sensory denervation using Spanish pepper 
(capsaicin), which reduced the concentrations of SP by ~60% (182). The study demonstrated that the residual SP levels 
after denervation correlated with the biomechanical tissue properties, i.e. transverse area, ultimate tensile strength, and 
stress at failure (182). Thus, higher residual SP levels after sensory neuropathy are associated with improved tensile 
strength and stress at failure in the healing of Achilles tendon. 
 
Taken together these studies strongly support the idea that neuronal derived factors have a powerful influence on the 
structure, function and healing capacity of dense connective tissues such as ligament and tendon. 
 
8.2. Stimulated neuronal signalling 
Recent work has explored the possibility that the exogenous administration of neuropeptides or neurotrophic factors 
lead to improved tendon and ligament healing. Local injections of SP combined with the neutral endopeptidases 
thiorphan and captopril were used as a treatment for Achilles tendon rupture in rats (183, 184). This resulted in dose 
dependent increases in fibroblast number at the injury site between 1 and 6 weeks after injury. Histological parameters 
of collagen type III occurrence and collagen organization were enhanced in the SP group as compared to the control 
group (184). Moreover, collagen fiber orientation and angiogenesis were also improved by SP treatment (183).  A 
second report, originating from the same laboratory utilizing the same model, showed that treatment with SP also 
increased stress at maximal load and work to maximal load in healing Achilles tendon, although stiffness was not 
improved compared to controls, and actual failure loads were not reported (185).  An interesting observation from one 
of these studies was that the SP treated group exhibited an accelerated withdrawal of sensory nerve fibers from the 
injury site during healing (184). This observation may be interesting in the context of human tendinopathy with 
protracted, pathological sensory nerve fiber ingrowth in the tendon. It may prove that SP injections could promote 
sensory nerve fiber withdrawal. 
 
Another recent study assessed the effect of exogenous neuropeptide administration on the healing of denervated 
ligaments in rats (181).  The aim was to restore or improve the healing responses of the medial collateral ligament in 
joints partially denervated by femoral nerve transection or surgical sympathectomy.  In this study SP, VIP and NPY all 
improved the healing of denervated MCLs.  In the case of SP and VIP treatment, several mechanical properties, 
including failure load and failure stress were reported to be higher than those of intact, uninjured MCL.  Treatment with 
SP, VIP and NPY also significantly improved the histological appearance of healing MCLs. Treated ligaments showed 
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more organized scars and the appearance of increased matrix production. Interestingly, CGRP did not improve any of 
the measured histological or mechanical parameters of MCL healing in this model. 
Another approach to the augmentation of neuronal factors in wound healing has been the use of nerve growth factor 
(NGF).  NGF was initially described and characterized as a trophic factor for specific neuronal populations in the 
peripheral nervous system (186). Subsequent studies have shown that NGF displays an extended spectrum of biological 
functions (138), and promotes skin wound healing in both rodents and humans (187-189).  NGF can promote ligament 
healing in rats (190).  In this study, NGF was continuously administered to the injury site for 7 days via an implanted 
mini-osmotic pump. At 7 days after injury, the fractional area occupied by blood vessels was increased, indicating that 
angiogenesis was promoted by NGF. By 14 days, in addition to increased vascular density, an increase in nerve fiber 
density was noted in the NGF treated specimens, although no differences in the mechanical properties of the ligament 
were detected. By 42 days after injury, nerve fiber and blood vessel densities were progressively increased, and scar 
mechanical properties were also significantly improved in the NGF group.  Thus, early exposure of injured tissues to 
exogenous NGF can lead to improved mechanical outcomes, a critical factor for structurally important tissues such as 
tendons and ligaments. Once optimized, this approach could have broad clinical implications. In this context it is 
interesting to notice that blockage of NGF with humanised monoclonal antibodies, eg. Tanezumab, in stage 3 clinical 
trials provides much more effective pain relief than traditional therapy with NSAIDs (191). However, balancing the 
inhibition of NGF-mediated pain and NGF-mediated regulation of tissue metabolism and repair will be a turning point 
whether NGF-targeted therapies will ever reach the patients in need (192). 
 
Tendon repair is reported to be promoted also by physical activity, which recently was shown to be linked to 
accelerated neuronal plasticity (193, 194). Morover, it has been demonstrated that physical activity and training leads to 
increased levels of various neuromediators, including SP and CGRP, which may be involved in regulating the healing 
response (193, 195). Interestingly, not only the neuromediator ligands are influenced by physical activity, but maybe 
more importantly, so are the neuromediator receptors. Thus, mRNA-levels for the SP- and CGRP-receptors are in 
mobilized tendons significantly increased at 17 days post tendon injury compared to immobilized controls (194). It may 
prove that enhanced tendon repair after physical activity is related to an increased peripheral sensitivity to sensory 
neuropeptide stimulation, implying an up-regulation of sensory neuropeptide receptors. Whether the sensory 
neuropeptide receptors elicit different responses or affect different cell types depending on loading conditions after 
injury has yet to be investigated. 
Other physical means of stimulating tendon repair include intermittent pneumatic compression, which applied 1 hour 
daily for two weeks post tendon injury induced a substantially elevated occurrence of SP by 110% and CGRP by 47% 
and simultaneously increased the fibroblast density by 53% and vessel density by 64% (196). Moreover, it was recently 
demonstrated that intermittent pneumatic compression could promote tendon repair in immobilized condition by 
increasing the biomechanical tissue properties; maximum force increased 65%, energy increased 168% and tendon 
length increased 25% (197). These results demonstrate that the compression treatment may have a substantial clinical 
impact, considering that immobilization is the basic principle in the treatment of ruptured tendons. In fact, clinical 
translation of the preclinical data has demonstrated that adjuvant intermittent pneumatic compression applied at least 6 
hours daily for two weeks post human Achilles tendon rupture upregulated the concentration of local essential 
metabolites in the paratenon of the healing tendon (102). The metabolite exhibiting the largest elevation, 1.5-times, 
after adjuvant compression treatment was glutamate (102). 
 
On the whole, our data indicate several interesting pharmacological and physical strategies of promoting neuronal 
pathways that could be further developed and employed to enhance tendon repair. 
 
9. PERSPECTIVE  
 
From the above discussions, it should be apparent that the neural contributions to normal tissue function, 
repair, and in some instances, pathology, support the contention that these neural regulatory components play essential, 
but as yet incompletely defined roles in mechanically active tissues such as tendons. While not present at high density, 
the neural elements are part of a highly complex integrative system that likely serves multiple roles in such tissues, 
contributing to homeostasis, proprioception and proper functioning of the various tissues in a joint to ensure that it 
works as a smooth machine (e.g. the joint as a mechanical organ concept). It is also likely that there are some aspects in 
common between the repair functions that such neural elements play in different tissues. However, considerable more 
investigation is needed to provide clarity with regard to the dynamic aspects of their role(s), and how neural elements 
are modulated by genetics, aging, and sex and co-morbidities. Some of this complexity likely serves fundamental roles 
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in repair and restoration of function, but it is clear also from the work of Salo et al (33, 34, 198) that innervation of 
normal joint tissues can decline with age in both rats and mice, and thus elevate risk for degenerative joint disease. 
Whether similar changes occur in tendons and ligaments throughout the body during aging and following events such 
as menopause, remains to be delineated. Similarly, how such changes impact the repair process in tendons and 
ligaments, as well as other connective tissues, also remain to be clarified. 
 
In particular, how impaired neural contributions resulting from aging, co-morbidities such as diabetes or genetic 
variables impact tissue repair will be critical to elucidate. Conversely, excessive or aberrant neural involvement in 
healing could also be detrimental to functional outcomes.  Clearly, the key missing piece to the puzzle is “what 
regulates the regulators?” and how does our understanding of the neural responses interface with the other elements of 
the host response to injury.  Hopefully a raised awareness of neural contributions to effective tissue repair will 
stimulate increased research in this area. 
 
From the above discussion, nerves certainly play an essential role in response to injury and healing following an injury. 
This conclusion is reinforced from preclinical animal studies and from patient populations.   The hierarchy of 
influences on healing is most certainly complex, with redundant systems operative to ensure a reasonable outcome even 
if the system as a whole is compromised by disease or aging. Interestingly, neural influences likely rank high in such a 
hierarchy based on what is known regarding connective tissue homeostasis, breakdown and healing in spinal cord 
injured people or preclinical models (199). Thus, spinal cord injured individuals exhibit alterations in these processes 
below the level of the injury, but retain regulatory control above the level of the injury. While likely multifactorial, this 
is evidence for the importance of the neural system in regulation. 
 
While nerves are likely central to regulation, one new area of research could also provide additional insights into 
chronic conditions such as tendinosis or other chronic abnormal “healing” situations where the responder cells (e.g. 
fibroblasts, myofibroblasts, and others) become altered. Thus, understanding the impact of epigenetics on 
responsiveness to regulatory systems such as nerves is currently emerging. Unlike genetics, which is the genome 
everyone inherits, epigenetic processes occur during life and result in modifications to the genome which in turn affect 
regulation of gene expression and function (  ). Thus, in conditions of chronic stress of various sorts (200), conditions 
of chronic exposure to environmental factors (201-203), and due to chronic stimulation, such as in rheumatoid pannus 
(204, 205) as examples, DNA can be modified by methylation or derivatization affecting outcomes. Whether such 
changes can occur with some regularity in tendinosis, or abnormal healing situations in tendons, ligaments and other 
connective tissues, or even be facilitated by neural influences, remains to be determined. However, it is likely that such 
alterations may relate to the neural regulation of tissue responses, and thus be relevant to better understanding both 
normal and “deviant” healing processes. 
 
In summary, considerable progress has been made on several of the “fronts” discussed above, to document the 
involvement and potential involvement of innervation to regulate and modulate repair of tendons and related 
connective tissues. It is also clear that further progress in this area will require a multi- or trans-disciplinary approach, 
bringing together molecular and cell biologists with neuroscientists and neurophysiologists, biomedical engineers, and 
clinician-scientists to advance the field. The field is certainly poised to make significant advances, and such advances 
may well be translated into new interventions to treat specific patient populations via the basic information generated, 
as well as identify those at risk (via genomic and epigenomic screening and other approaches) for loss of neural 
contributions to maintaining connective tissue function and integrity. 
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Figure 1.  A-C. Immunofluorescence micrographs of longitudinal sections through the Achilles tendon after incubation 
with antisera to Noradrenaline (NA) (A), NPY (B) and VIP (C). NA-positive fibers are mainly found as nerve terminals 
in outer layers of the blood vessel walls. The NPY-positive fibers are arranged as nerve terminals in the vessel walls. 
VIP-positive nerves are arranged as a “fence”, surrounding the proper tendon, of small varicosities in the paratenon. t = 
tendon tissue; Pt = paratenon; Bar = 50 µm. Reproduced with permission from (58). 
 
Figure 2. A-D. Immunofluorescence micrographs of longitudinal sections through the Achilles tendon after double 
staining (co-localization) with antisera to SP and CGRP (A), SP and GAL (B) LE and DOR (C) and incubation with 
antisera to ME (D). A co-existence of SP and CGRP is seen in nerve fibers localised in the paratenon (A), indicating 
possible pro-inflammatory actions. Moreover, SP is also co-localised with GAL (B), which may reflect anti-
inflammatory actions. The immunoreactivity displaying co-existence of LE and DOR is seen as free nerve endings in 
the paratenon (C), which indicates a potential peripheral anti-nociceptive system. ME immunoreaction is localised in a 
vessel wall (D). t = tendon tissue; Pt = paratenon; Bar = 50 µm. Reproduced with permission from (76, 86). 
 
Figure. 3. A-C. Overview micrographs of longitudinal sections through the Achilles tendon built up by putting together 
computerized images of smaller micrographs. Incubation with antisera to general nerve marker PGP. Micrographs 
depict the proximal half of the Achilles tendon at increasing magnification in figures (A-C). Arrows denote varicosities 
and nerve terminals. The typical vascular localization of NPY is depicted in (B), whereas the free nerve endings are 
typical localization of SP (C). The immunoreactivity is seen in the paratenon and surrounding loose connective tissue, 
whereas the proper tendinous tissue, notably, is almost devoid of nerve fibers pt = paratenon. Reproduced with 
permission from (80). 
 
Figure 4. A-B. Overview micrographs of longitudinal sections through the Achilles tendon two weeks post rupture 
built up by putting together computerized images of smaller micrographs. Incubation with antisera to a nerve growth 
marker, GAP-43. Micrographs depict the proximal half of the Achilles tendon at increasing magnification in figures 
(A-B). Arrows denote varicosities and nerve terminals. The GAP-positive fibers, indicating new nerve fiber ingrowth, 
are abundantly observed in the healing proper tendon tissue. Reproduced with permission from (80). 
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Figure 5. Area occupied by nerve fibers (%) immunoreactive to GAP and PGP in relation to total area, in the mid third 
of the tendon, over 16 weeks post rupture (mean±s.e.m.). Reproduced with permission from (80). 
 
Figure 6. Area occupied by nerve fibers (%) immunoreactive to SP, CGRP and GAL in relation to total area, in the mid 
third of the tendon, over 16 weeks post rupture (mean±s.e.m.). Reproduced with permission from (103). 
 
Figure 7. A-H. Photomontage of typical high power images of immunohistochemically stained nerve fibers (arrows) at 
different time points after medial collateral ligament injury in the rabbit.  Scale bar = 20 microns At two weeks CGRP 
fibers appear very fine in the early scar. At 6 weeks there is the appearance of CGRP-immunoreactive growth cone like 
structures (large arrow head) and sprouting as well as a predominantly perivascular distribution of fibers. Fourteen 
weeks post-injury there are fewer CGRP-immunoreactive fibres in the scar with most found again in the epiligament. 
All SP positive profiles were found to be perivascular at 2 weeks after injury. Similar to the appearance at 2 weeks, SP 
positive profiles were only found associated with proliferating vessels within the scar at later time points. The letter v 
indicates a vessel lumen.  Scale bar at bottom right = 20 microns and applies to the entire montage. Typical image of 
NPY containing fibres associated with small arterial vessels in a 6 week post-injury scar.  The letter v indicates a vessel 
lumen. Six weeks post-injury, staining for the marker PGP 9.5, which stains all nerve fibres, revealed a pattern that 
combined aspects of the other markers, with most fibres in a perivascular location, and some free in the scar matrix. 
Reproduced with permission from (78). 
 
Figure 8. A-B. Immunofluorescence micrograph of longitudinal sections through healing Achilles tendon 1- (A) and 2- 
(B) weeks post rupture after incubation with antisera to CGRP. Nerve fibers immunoreactive to CGRP at week 1 are 
seen as vascular and free nerve endings in the loose connective tissue (A). At week 2, CGRP- immunoreactivity occurs 
mainly in the healing tendinous tissue as sprouting free nerve fibers (B). v = blood vessel; lct = loose connective tissue; 
t = proper tendon tissue; Bar = 50 µm. Reproduced with permission from (103). 
 
Figure 9. A-B. Immunofluorescence micrographs of longitudinal sections of healthy Achilles tendon (A) and 
tendinosis tissue (B) after immunostaining for SP. Arrows denote varicosities and nerve terminals. The micrograph 
illustrates SP-positive nerve fibres in close vicinity to a proliferated vessel (B). v = blood vessel. Bar = 50 µm. 
Reproduced with permission from (79). 
 
Figure 10. A-B. Hematoxylin and eosin micrographs of longitudinal sections through the patellar tendon of healthy 
control (A) and painful tendinopathy (B). Arrows denote tenocytes. The healthy tendon is homogeneous, with 
organized parallel collagen structure and thin, elongated tenocytes (A). The tendinopathy, on the other hand, is marked 
by collagen disorganization, increased cell count, activated tenocytes, and vascular ingrowth in the tendon proper (B). 
V = blood vessel.  Bar = 50 µm. Reproduced with permission from (79). 
 
Figure 11. A-B. Immunofluorescence micrographs of longitudinal sections through the patellar tendon of healthy 
control (A) and painful tendinopathy (B) stained for TH (a marker for noradrenaline). Arrows denotes nerve fibers. In 
the healthy tendon, a strong relation is seen between blood vessels and TH positive nerves (A). In painful tendinopathy, 
a decreased number of TH positive nerves, which are blood vessel related is seen. V = blood vessel. Bar = 50 µm. 
Reproduced with permission from (79). 
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Table 1.  Neuronal pathways in tendons 
 
PATHWAY SIGNALLING MEDIATOR RECEPTOR ACTIONS 
Autonomic 
Sympathetic 
Noradrenaline alpha-,beta- adrenoceptors  
Pro-(anti)-
inflammatory 
Neuropeptide Y Y1, Y21,Y32 
Parasympathetic 
Acetylcholine  Nicotinic, muscarinic   
Anti-





Substance P Neurokinin 1 
Pro-
inflammatory 
CGRP  CRLR, RAMP-1 
Neurokinin A Neurokinin 22 
NKB*, NPK*, NPG* Neurokinin 32 
Opioid  





Dynorphins: DYN B1 kappa-opiod receptor1 
Endomorphins1 mu-opiod receptor1 
Nociceptin1 N/OFQ receptor2 
Opioid like: Galanin  Galanin receptor 1-32  
Opioid like: Somatostatin Somatostatin receptor 1-52 
Excitatory  Glutamatergic  Glutamate 
NMDA  
Cell-proliferative 
mGluR11, mGluR5-7  
AMPA2 
Kainate2 
1 Not detected in tendon 2 Not yet assessed in tendon, VIP = vasoactive intestinal polypeptide, VPAC = Vasoactive 
intestinal peptide receptor, PAC1 = Pituitary adenylate cyclase-activating polypeptide type I receptor, CGRP = 
calcitonin gene-related peptide, CRLR = calcitonin receptor-like receptor,RAMP-1 = receptor activity-modifying 
protein 1, NKB = neurokinin B, NPK = neuropeptide K, NPG =neuropeptide-g, LE = leucine enkephalin, ME = 
Methionine-enkephalin, MEAP = methionine-enkephalin-arginine-phenylalanine N/OFQ = Nociceptin/orphanin 
FQ peptide,  NMDA = N-methyl-D-aspartate receptor, mGluR = metabotropic glutamate receptors, AMPA =  alfa-




Table 2.  Neuronal alterations in tendinopathy 
 
 






Cell proliferation / 
differentiation 
Neuropeptide Y2  Y1  é Cell proliferation / differentiation 
Parasympathetic 
Acetylcholine  é Nicotinic2,muscarinic é Cell proliferation / differentiation  





Substance P   é Neurokinin 1   é 
 
Tenocyte / endothelial cell 
proliferation, MMP-3  é 
CGRP2 CRLR2, RAMP-12 
Neurokinin A2 Neurokinin 22 
Opioid  
Enkephalins2 delta-opiod receptor2  
 
Cell proliferation / 
differentiation 
Cannabinoids Cannabinoid receptor 1 é 
Galanin2 Galanin receptor 1-32  
Somatostatin2 Somatostatin receptor 1-52 
Excitatory  Glutamatergic  Glutamate    é 
NMDA                      é 
Cell proliferation / 
differentiation   
Phosfo-NMDA1            é 
mGluR5           é 
mGluR6-7     è 
2 Not yet assessed in tendinopathy, VIP = vasoactive intestinal polypeptide, VPAC = Vasoactive intestinal peptide 
receptor, PAC1 = Pituitary adenylate cyclase-activating polypeptide type I receptor, CGRP = calcitonin gene-
related peptide, CRLR = calcitonin receptor-like receptor,RAMP-1 = receptor activity-modifying protein 1, NKB 
= neurokinin B, NPK = neuropeptide K, NPG =neuropeptide-g, LE = leucine enkephalin, ME = Methionine-
enkephalin, MEAP = methionine-enkephalin-arginine-phenylalanine N/OFQ = Nociceptin/orphanin FQ peptide, 
 NMDA = N-methyl-D-aspartate receptor, mGluR = metabotropic glutamate receptors, AMPA =  alfa-amino-3-
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